AlphaCore Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

AlphaCore Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.62M	Buy	3,258 +632	+24%	+$280K	0.03%	355
2026 Q1	$1.17M	Sell	2,626 -2,254	-46%	-$1.05M	0.03%	349
2025 Q4	$2.21M	Sell	4,880 -375	-7%	-$162K	0.05%	252
2025 Q3	$2.06M	Buy	5,255 +224	+4%	+$93.6K	0.07%	187
2025 Q2	$2.24M	Buy	5,031 +4,052	+414%	+$1.87M	0.09%	177
2025 Q1	$475K	Buy	979 +51	+5%	+$23.8K	0.04%	278
2024 Q4	$374K	Sell	928 -22	-2%	-$10.2K	0.08%	148
2024 Q3	$442K	Buy	950 +2	+0.2%	+$961	0.1%	121
2024 Q2	$444K	Buy	+948	New	+$411K	0.11%	114

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AlphaCore Capital's VRTX Position: Q2 2026 in Review

AlphaCore Capital increased its Vertex Pharmaceuticals (VRTX) stake by 24% in Q2 2026, buying an estimated $280K and bringing the position to 3,258 shares worth $1.62M. The position accounts for 0.03% of the portfolio, ranked #355.

AlphaCore Capital first reported a position in VRTX in Q2 2024 and has held it in 9 quarters since. The position peaked at $2.24M in Q2 2025. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

AlphaCore Capital held 3,258 shares of Vertex Pharmaceuticals worth $1.62M as of Q2 2026.
AlphaCore Capital bought 632 Vertex Pharmaceuticals shares in Q2 2026, an estimated $280K.
Vertex Pharmaceuticals made up 0.03% of AlphaCore Capital's portfolio in Q2 2026, its #355 holding.
AlphaCore Capital first reported a position in Vertex Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
AlphaCore Capital's Vertex Pharmaceuticals position peaked at $2.24M in Q2 2025.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.